Supplements
Effectiveness rated 45 due to promising but weak evidence: one n=6 case series (conflict of interest, not RCT) showing plaque regression via glycocalyx support, plus small open-label trials on rhamnan sulfate for NO/lipids/BP, and moderate/strong data on secondary polyphenols (e.g., green tea catechins reduce LDL per meta-analyses; grape seed lowers BP). Lacks large RCTs/meta-analyses for arterial plaque reduction. Safety high (95) as no side effects in studies/FDA reports. Quality moderate (55)
Average (59/100) - Effectiveness rated 45 due to promising but weak evidence: one n=6 case series (conflict of interest, not RCT) showing plaque regression via glycocalyx support, plus small open-label trials on rhamnan sulfate for NO/lipids/BP, and moderate/strong data on secondary polyphenols (e.g., green tea catechins reduce LDL per meta-analyses; grape seed lowers BP). Lacks large RCTs/meta-analyses for arterial plaque reduction. Safety high (95) as no side effects in studies/FDA reports. Quality moderate (55) for cGMP/purity claims but penalized for opaque proprietary 900mg blend (unknown rhamnan sulfate dose vs. study blend), absence of third-party certifications, and high cost vs. cheaper polyphenol alternatives like standalone grape seed (150mg ~$10/mo) or green tea extract.